GL1X · GenesisL1 explorer

MolNFT v1 · #81015 · protein

Ecp-cleaved actin in complex with spir domain D

3UE5 · Actin, alpha skeletal muscle: “Ecp-cleaved actin in complex with spir domain D”. X-ray diffraction, 3 ligands (ATP, CA, CL), 2 pockets (best druggability 0.75). MolNFT v1 #81015 on GenesisL1: 3D structure, binding sites and pockets…

PDB
3UE5
Type
protein
Length
389 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Actin, alpha skeletal muscle; Protein spire
UniProt
P68135, Q9U1K1
Ligands
ATP, CA, CL
Pockets
2 · best druggability 0.75

Structure

x-ray diffraction · 2 distinct chains · 43% helix, 20% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AActin, alpha skeletal muscleprotein36443% helix, 21% strandP68135
BProtein spireprotein2544% helix, 4% strandQ9U1K1

Ligands and binding sites

  • ATP · Adenosine-5'-triphosphate · ligand · chains A
  • CA · Calcium ion · metal · chains A
  • CL · Chloride ion · ion · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13720.750.8650CA, ATP
21750.570.8129empty

Interfaces

1 interface between chains.

  • A–B · 854 Ų buried · 7 hydrogen bonds · protein-protein

Compared structures

  • 3UE5 · ECP-cleaved Actin in complex with Spir domain D · the same entry in another collection · chain A against A, TM-score 1.00
  • P68135 · AlphaFold monomer V2.0 prediction for actin, alpha skeletal muscle (P68135) · a predicted model of the same protein · chain A against A, TM-score 0.97
  • Q9U1K1 · AlphaFold monomer V2.0 prediction for protein spire (Q9U1K1) · a predicted model of the same protein · chain B against A, TM-score 0.51

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.